Tumor Microenvironment (TME) Pathway: Key Components and Signaling Mechanisms

Understanding the tumor microenvironment structure

The TME is a specialized, pro-tumorigenic niche formed by the interaction between malignant cells and the host tissue. Unlike healthy tissue, it is characterized by distorted blood vessels, a stiffened extracellular matrix and a chronically inflamed biochemical profile.

These structural changes are not random. They arise from continuous signaling between tumor cells and stromal components, gradually reshaping the tissue architecture. The result is a physically dense and metabolically stressed environment that exerts selective pressure on cancer cells, favoring the survival of clones that are most efficient at immune evasion.

Key characteristics of a malignant microenvironment:

• Architectural distortion: Cancer-associated fibroblasts (CAFs) deposit and cross-link collagen, creating a dense and rigid extracellular matrix. Increased matrix stiffness alters cell behavior through integrin signaling and mechanical stress pathways. Elevated interstitial fluid pressure also compresses nearby blood vessels and lymphatic channels, limiting drug delivery and trapping immune cells in the stroma. (1,2)
• Vascular abnormalities: Tumor-driven angiogenesis, largely mediated by VEGF, produces blood vessels that are disorganized and leaky. Despite increased vessel formation, blood flow is inefficient, leading to regions of unstable oxygen supply. These hypoxic areas stabilize HIF-1α and promote recruitment of immunosuppressive cells. (2,3)
• Biochemical Landscape: The TME is typically acidic, hypoxic and nutrient-depleted due to rapid glycolysis and poor perfusion. Low pH and reduced glucose or amino acid availability impair cytotoxic T-cell activity while favoring cancer cells that can adapt to metabolic stress. (4)

The TME acts as a biological selection system. Mechanical stress, vascular dysfunction and metabolic imbalance work together to favor cancer cells that adapt to hypoxia, nutrient scarcity and immune pressure – shaping both disease progression and therapeutic response.

Tumor microenvironment components

The tumor microenvironment is composed of interacting cellular and acellular elements that collectively regulate tumor progression. Its core components include immune cells, stromal fibroblasts, vascular networks and the extracellular matrix (ECM), all embedded within a dynamically evolving biochemical environment. (4,5)

• Immune cells: These include tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), neutrophils, regulatory T cells and cytotoxic T lymphocytes. While some retain anti-tumor potential, many are functionally reprogrammed toward immunosuppressive phenotypes that protect malignant cells.
• Stromal and vascular cells: The stroma is dominated by cancer-associated fibroblasts (CAFs), which reshape the ECM and regulate tissue stiffness. The vascular compartment consists of abnormal endothelial networks formed through dysregulated angiogenesis, resulting in unstable perfusion and localized hypoxia.
• Extracellular matrix: The ECM acts as both a scaffold and a signaling platform, transmitting biochemical and mechanical cues that influence cell survival, migration and differentiation.

Rather than serving as a passive background, each component functions as an interdependent regulator of tumor survival, continuously exchanging signals that reinforce tumor-supportive conditions.

Cellular components of the TME pathway

The cellular landscape of the TME is defined by a tug-of-war between suppressed effector cells (T-cells, NK cells) and tumor-supportive stromal and immune cells (CAFs, MDSCs, TAMs) that protect the tumor.

Rather than acting independently, these populations operate within a coordinated signaling network that amplifies tumor-supportive conditions.

Cancer-associated fibroblasts

Cancer-associated fibroblasts (CAFs) are the primary stromal cells within the TME, distinguished by a myofibroblast-like phenotype and elevated expression of markers such as fibroblast activation protein (FAP). (6)

Unlike normal tissue fibroblasts, CAFs are persistently activated and function as central regulators of extracellular matrix (ECM) remodeling and tumor-stroma communication. They deposit and cross-link collagen, increasing tissue stiffness. Through secretion of TGF-β, PDGF and other growth factors, they reinforce pro-invasive signaling circuits and promote epithelial-to-mesenchymal transition (EMT). (7) In parallel, CAF-derived cytokines often block dendritic cells (DCs) from accessing the tumor core, preventing the immune system from effectively presenting tumor antigens to T-cells.

Beyond structural remodeling, CAFs influence angiogenesis by secreting pro-angiogenic mediators. The resulting dense stroma can compress blood vessels and restrict drug penetration, contributing to therapeutic resistance.

CAFs act as the engine of TME structural resistance. They don't just support the tumor; they physically shield it by increasing interstitial fluid pressure, preventing chemotherapy drugs and immune cells from reaching the malignant core.

Myeloid-derived suppressor cells

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that expand under pathological conditions to suppress anti-tumor immunity.

Within the TME, they accumulate in response to tumor-derived growth factors and inflammatory mediators. MDSCs inhibit T-cell activity primarily through metabolic interference. Upregulation of arginase-1 depletes arginine, an amino acid essential for T-cell proliferation. Expression of inducible nitric oxide synthase (iNOS) increases nitric oxide production, disrupting T-cell receptor signaling. MDSCs also produce reactive oxygen species (ROS) through NADPH oxidase (NOX2), which can impair T-cell receptor signaling and contribute to antigen-specific suppression. (8,9)

MDSC suppression is primarily metabolic. They turn the TME into a nutrient desert, where effector T-cells starve, rendering the immune system functionally paralyzed even if immune cells are present.

Tumor-associated macrophages and neutrophils

Tumor-associated macrophages (TAMs) and tumor-associated neutrophils (TANs) are innate immune cells that are functionally reprogrammed by tumor-derived cytokines (like CCL2 and CXCL8) to support tumor progression rather than elimination.

• TAMs: Frequently adopting an M2-like polarization state, TAMs secrete IL-10 and TGF-β to dampen inflammation. Crucially, they are major producers of VEGF, directly linking immune suppression to vascular expansion. This M2 phenotype promotes angiogenesis, suppresses cytotoxic T-cell activity and supports tissue remodeling. (10)
• TANs: Recruited through chemokines such as CXCL8, TANs can suppress CD8+ T-cell activity via reactive oxygen species (ROS) production. These ROS also cause DNA damage in nearby cells, fueling genetic instability and tumor evolution (11)

TAM plasticity is a critical vulnerability. While healthy macrophages destroy pathogens, the TME hacks them to become the tumor's primary source of growth factors. Reverting them to an M1 phenotype is a major therapeutic goal.

Key signaling and metabolic mechanisms in the TME

The TME pathways coordinate immune evasion through an interconnected matrix of physical stress, hijacked signaling axes and metabolic reprogramming.

These mechanisms do not function independently; instead, they form a dynamic regulatory network that adapts to physical stress, inflammatory signals and therapeutic pressure.

Master signaling pathways: The TME communication network

The TME relies on defined signaling axes to synchronize stromal activation, immune suppression and vascular expansion. (4) These pathways function as regulatory nodes that translate environmental stress into coordinated cellular responses.

Within this framework, TGF-β signaling drives stromal activation and immune tolerance, while VEGF signaling sustains aberrant angiogenesis. Additional proliferative cascades, including WNT/β-catenin signaling and EGFR and MAPK pathways, further reinforce tumor cell survival. (7)

TME signaling is networked rather than linear. Hypoxia triggers VEGF (angiogenesis) and PD-L1 (immune checkpoints) simultaneously. Targeting a single pathway often fails, because the network adapts.

Metabolic reprogramming and the Warburg effect

Metabolic reprogramming is a hallmark of cancer, and within the TME, cancer cells and immune cells compete for limited nutrients. This competition is dominated by the Warburg effect, in which tumor cells preferentially use aerobic glycolysis even in the presence of oxygen. (12)

Accelerated glycolysis leads to lactate accumulation and extracellular acidification. Reduced pH directly impairs T-cell proliferation and cytokine production, creating a biochemical barrier to effective immune surveillance. Simultaneously, rapid glycolysis and nutrient consumption within the TME deprive effector lymphocytes of substrates required for activation.

Beyond fuel competition, metabolic shifts in the TME can disrupt gene regulation in immune cells. Accumulation of oncometabolites and depletion of key enzymatic cofactors impair normal epigenetic maintenance, which can lock effector immune cells into dysfunctional states and further blunt anti-tumor surveillance.

The Warburg effect is not just about energy; it is a weapon. By acidifying the environment and depleting nutrients, the tumor creates a metabolic barrier that acts like a physical wall. (13)

Hypoxia: The master metabolic switch

Local hypoxia (low oxygen) is a central driver of the TME’s aggressive phenotype, stabilizing hypoxia-inducible factor 1-alpha (HIF-1α) and activating transcriptional programs that promote survival and immune evasion. (14)

Reduced oxygen availability arises from abnormal vasculature and high metabolic demand. HIF-1α directly upregulates VEGFA to promote angiogenesis and induces chemokines such as CCL2 that recruit immunosuppressive TAMs and MDSCs. (15) It also enhances glycolytic enzyme expression, reinforcing the Warburg phenotype.

Hypoxia bridges structural dysfunction with metabolic adaptation. It ensures that as the tumor grows and runs out of oxygen, it automatically triggers the pathways needed to spread (metastasis) and hide (immunosuppression).

Therapeutic targeting of the TME

Therapeutic targeting of the tumor microenvironment represents a strategic shift in oncology that focuses on normalizing the tumor’s surroundings rather than solely attacking malignant cells.

Strategies for TME modulation

Because the TME operates as an integrated signaling and metabolic network, effective intervention often requires simultaneous modulation of multiple components rather than single-pathway inhibition. Therapeutic strategies targeting the TME are designed to interfere with the cellular and molecular circuits that sustain immune evasion and structural resistance.

• Immune checkpoint blockade (ICB): Immune checkpoint inhibitors targeting PD-1, PD-L1 or CTLA-4 disrupt exhaustion signals within the TME, enabling reactivation of tumor-infiltrating lymphocytes (TILs). (16)
• Stroma normalization: Targeting CAFs and extracellular matrix reduces tissue stiffness and interstitial fluid pressure. Inhibiting TGF-β signaling can soften the tumor architecture, improving vascular perfusion and drug delivery.
• TAM repolarization: Strategies aimed at shifting macrophages from an M2-like, pro-tumor phenotype toward an M1-like, inflammatory state (often using IL-12 or CD40 agonists) seek to restore antigen presentation capacity.
• Metabolic intervention: Targeting metabolic enzymes such as IDO or arginase-1 aims to reverse nutrient depletion. By restoring arginine and tryptophan availability, these approaches attempt to refuel immune effector cells. (9)

The TME is the primary reason why many potent drugs fail in vivo despite succeeding in vitro. Successful modern therapy requires a dual-action approach: Killing the cancer cells while simultaneously rehabilitating the microenvironment to prevent recurrence.

References

1. Deng B, Zhao Z, Kong W, Han C, Shen X, Zhou C. Biological role of matrix stiffness in tumor growth and treatment. J Transl Med. 2022;20(1):540. https://doi.org/10.1186/s12967-022-03768-y
2. Goel S, Duda DG, Xu L, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 2011;91(3):1071-1121. https://doi.org/10.1152/physrev.00038.2010
3. Dudley AC. Tumor endothelial cells. Cold Spring Harb Perspect Med. 2012;2(3):a006536-a006536. https://doi.org/10.1101/cshperspect.a006536
4. Khalaf K, Hana D, Chou JTT, Singh C, Mackiewicz A, Kaczmarek M. Aspects of the tumor microenvironment involved in immune resistance and drug resistance. Front Immunol. 2021;12. https://doi.org/10.3389/fimmu.2021.656364
5. Goenka A, Khan F, Verma B, et al. Tumor microenvironment signaling and therapeutics in cancer progression. Cancer Commun. 2023;43(5):525-561. https://doi.org/10.1002/cac2.12416
6. Nurmik M, Ullmann P, Rodriguez F, Haan S, Letellier E. In search of definitions: Cancer‐associated fibroblasts and their markers. Int J Cancer. 2020;146(4):895-905. https://doi.org/10.1002/ijc.32193
7. Batlle E, Massagué J. Transforming growth factor-β signaling in immunity and cancer. Immunity. 2019;50(4):924-940. https://doi.org/10.1016/j.immuni.2019.03.024
8. Alvear-Arias JJ, Carrillo C, Villar JP, et al. Expression of Hv1 proton channels in myeloid-derived suppressor cells (MDSC) and its potential role in T cell regulation. Proceedings of the National Academy of Sciences. 2022;119(15). https://doi.org/10.1073/pnas.2104453119
9. Mondanelli G, Ugel S, Grohmann U, Bronte V. The immune regulation in cancer by the amino acid metabolizing enzymes ARG and IDO. Curr Opin Pharmacol. Elsevier Ltd. 2017;35:30-39. https://doi.org/10.1016/j.coph.2017.05.002
10. Xu J, Ding L, Mei J, et al. Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments. Signal Transduct Target Ther. 2025;10(1):268. https://doi.org/10.1038/s41392-025-02325-5
11. Que H, Fu Q, Lan T, Tian X, Wei X. Tumor-associated neutrophils and neutrophil-targeted cancer therapies. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2022;1877(5):188762. https://doi.org/10.1016/j.bbcan.2022.188762
12. Vaupel P, Multhoff G. Revisiting the Warburg effect: historical dogma versus current understanding. J Physiol. 2021;599(6):1745-1757. https://doi.org/10.1113/JP278810
13. Barba I, Carrillo-Bosch L, Seoane J. Targeting the Warburg effect in cancer: where do we stand? Int J Mol Sci. Multidisciplinary Digital Publishing Institute (MDPI). 2024;25(6). https://doi.org/10.3390/ijms25063142
14. Paredes F, Williams HC, San Martin A. Metabolic adaptation in hypoxia and cancer. Cancer Lett. Elsevier Ireland Ltd. 2021;502:133-142. https://doi.org/10.1016/j.canlet.2020.12.020
15. Tamura R, Tanaka T, Akasaki Y, Murayama Y, Yoshida K, Sasaki H. The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications. Medical Oncology. 2020;37(1):2. https://doi.org/10.1007/s12032-019-1329-2
16. Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8. https://doi.org/10.3389/fphar.2017.00561